Berdon syndrome
MeSH: C536138ORPHA: 22412 Treatments Available
Overview
syndrome that is characterized by marked dilatation of the bladder and microcolon and decreased intestinal peristalsis
Available Treatments (2)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Total Parenteral Nutrition Cold Chain | IV infusion, customized formulations | FDA Approved | 11 | 5d |
| Erythromycin | Oral tablets 250mg, 500mg; IV infusion; Oral suspension 200mg/5mL | FDA Approved | 8 | 2d |
Clinical Presentation
Signs and symptoms associated with Berdon syndrome, sourced from HPO and Orphanet clinical annotations.
MegacystisNausea and vomitingAbdominal distentionMicrocolonHypoperistalsisMulticystic kidney dysplasiaHydroureterPolyhydramniosIntestinal malrotationAbnormality of the gastrointestinal tractCryptorchidismUmbilical herniaOmphaloceleAbnormal cardiovascular system morphologyNeoplasm of the heartSepsis
Classification & Codes
MeSH Code
C536138Orphanet Code
ORPHA:2241Berdon syndrome
| MeSH | C536138 |
| Orphanet | ORPHA:2241 |
| Treatments | 2 drug(s) |
| Symptoms on record | 16 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO